Aldosterone contributes to progressive kidney disease through multiple genomic and nongenomic pathways, providing a mechanistic rationale for mineralocorticoid receptor blockade in CKD.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ponda et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: